JP4180114B2 - Ｔｎｆ受容体関連因子（ｔｒａｆ）のモジュレーター、その製造法および使用 - Google Patents

Ｔｎｆ受容体関連因子（ｔｒａｆ）のモジュレーター、その製造法および使用 Download PDF

Info

Publication number: JP4180114B2
Authority: JP; Japan
Prior art keywords: protein; traf2; nik; proteins; sequence
Prior art date: 1996-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP53509997A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000507826A (ja

Inventor

ワラク、デビッド

マリニン、ニコライ

ボールディン、マーク

コバレンコ、アンドレイ

メト、イゴール

Original Assignee

イエダリサーチアンドディベロップメントカンパニーリミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-02

Filing date

1997-04-01

Publication date

2008-11-12

1996-04-02 Priority claimed from IL11780096A external-priority patent/IL117800A0/xx

1996-08-26 Priority claimed from IL11913396A external-priority patent/IL119133A0/xx

1997-04-01 Application filed by イエダリサーチアンドディベロップメントカンパニーリミテッド filed Critical イエダリサーチアンドディベロップメントカンパニーリミテッド

2000-06-27 Publication of JP2000507826A publication Critical patent/JP2000507826A/ja

2008-11-12 Application granted granted Critical

2008-11-12 Publication of JP4180114B2 publication Critical patent/JP4180114B2/ja

2017-04-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 132
238000004519 manufacturing process Methods 0.000 title claims abstract description 11
230000008569 process Effects 0.000 title description 12
102000008889 TNF receptor-associated factor TRAF Human genes 0.000 title 2
108050000808 TNF receptor-associated factor TRAF Proteins 0.000 title 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 280
102000004169 proteins and genes Human genes 0.000 claims abstract description 267
239000012634 fragment Substances 0.000 claims abstract description 117
230000027455 binding Effects 0.000 claims abstract description 75
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 63
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims abstract description 20
102000003298 tumor necrosis factor receptor Human genes 0.000 claims abstract description 20
108090000925 TNF receptor-associated factor 2 Proteins 0.000 claims description 193
102000004393 TNF receptor-associated factor 2 Human genes 0.000 claims description 193
230000000694 effects Effects 0.000 claims description 93
108010057466 NF-kappa B Proteins 0.000 claims description 89
239000013598 vector Substances 0.000 claims description 58
239000002299 complementary DNA Substances 0.000 claims description 52
239000003446 ligand Substances 0.000 claims description 52
108020004414 DNA Proteins 0.000 claims description 43
150000001413 amino acids Chemical class 0.000 claims description 27
230000014509 gene expression Effects 0.000 claims description 26
125000003275 alpha amino acid group Chemical group 0.000 claims description 24
238000012216 screening Methods 0.000 claims description 22
108010014632 NF-kappa B kinase Proteins 0.000 claims description 21
239000002773 nucleotide Substances 0.000 claims description 21
125000003729 nucleotide group Chemical group 0.000 claims description 21
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
238000001042 affinity chromatography Methods 0.000 claims description 10
239000000284 extract Substances 0.000 claims description 8
238000004458 analytical method Methods 0.000 claims description 6
238000001086 yeast two-hybrid system Methods 0.000 claims description 6
230000002068 genetic effect Effects 0.000 claims description 5
238000002955 isolation Methods 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
239000012504 chromatography matrix Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 2
230000001131 transforming effect Effects 0.000 claims description 2
102000003945 NF-kappa B Human genes 0.000 claims 1
238000010828 elution Methods 0.000 claims 1
230000004481 post-translational protein modification Effects 0.000 claims 1
102000014914 Carrier Proteins Human genes 0.000 abstract description 101
108091008324 binding proteins Proteins 0.000 abstract description 101
102000001708 Protein Isoforms Human genes 0.000 abstract description 69
108010029485 Protein Isoforms Proteins 0.000 abstract description 69
235000018102 proteins Nutrition 0.000 description 249
210000004027 cell Anatomy 0.000 description 148
102000005962 receptors Human genes 0.000 description 115
108020003175 receptors Proteins 0.000 description 115
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 83
108090000765 processed proteins & peptides Proteins 0.000 description 65
108060008682 Tumor Necrosis Factor Proteins 0.000 description 58
108020004635 Complementary DNA Proteins 0.000 description 52
102000004196 processed proteins & peptides Human genes 0.000 description 51
238000010804 cDNA synthesis Methods 0.000 description 49
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 48
230000006698 induction Effects 0.000 description 47
102000003390 tumor necrosis factor Human genes 0.000 description 46
230000001404 mediated effect Effects 0.000 description 43
101150028668 APO1 gene Proteins 0.000 description 36
230000003993 interaction Effects 0.000 description 34
102100027651 TRAF-interacting protein with FHA domain-containing protein A Human genes 0.000 description 33
101710144564 TRAF-interacting protein with FHA domain-containing protein A Proteins 0.000 description 33
102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 33
108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 33
229920001184 polypeptide Polymers 0.000 description 32
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 29
235000001014 amino acid Nutrition 0.000 description 29
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 27
108091000080 Phosphotransferase Proteins 0.000 description 23
102000020233 phosphotransferase Human genes 0.000 description 23
239000000427 antigen Substances 0.000 description 22
230000003834 intracellular effect Effects 0.000 description 21
239000007787 solid Substances 0.000 description 21
230000004913 activation Effects 0.000 description 20
108091007433 antigens Proteins 0.000 description 20
102000036639 antigens Human genes 0.000 description 20
238000003556 assay Methods 0.000 description 19
239000003112 inhibitor Substances 0.000 description 19
239000008194 pharmaceutical composition Substances 0.000 description 18
238000006467 substitution reaction Methods 0.000 description 18
108091034117 Oligonucleotide Proteins 0.000 description 17
210000000170 cell membrane Anatomy 0.000 description 17
238000003752 polymerase chain reaction Methods 0.000 description 17
230000009471 action Effects 0.000 description 16
230000030833 cell death Effects 0.000 description 16
239000000523 sample Substances 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 15
108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 15
241000700605 Viruses Species 0.000 description 15
230000001413 cellular effect Effects 0.000 description 15
230000006870 function Effects 0.000 description 15
102000039446 nucleic acids Human genes 0.000 description 15
108020004707 nucleic acids Proteins 0.000 description 15
150000007523 nucleic acids Chemical class 0.000 description 15
239000013615 primer Substances 0.000 description 14
210000001519 tissue Anatomy 0.000 description 14
108090000994 Catalytic RNA Proteins 0.000 description 13
102000053642 Catalytic RNA Human genes 0.000 description 13
101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 13
102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 13
230000004071 biological effect Effects 0.000 description 13
108091092562 ribozyme Proteins 0.000 description 13
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
108091008604 NGF receptors Proteins 0.000 description 12
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
230000004068 intracellular signaling Effects 0.000 description 12
230000002018 overexpression Effects 0.000 description 12
238000012360 testing method Methods 0.000 description 12
238000010396 two-hybrid screening Methods 0.000 description 12
101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 11
101150064015 FAS gene Proteins 0.000 description 11
108050006617 Interleukin-1 receptor Proteins 0.000 description 11
102000019223 Interleukin-1 receptor Human genes 0.000 description 11
101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 11
230000003302 anti-idiotype Effects 0.000 description 11
238000001514 detection method Methods 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
230000036961 partial effect Effects 0.000 description 11
238000010561 standard procedure Methods 0.000 description 11
102100026693 FAS-associated death domain protein Human genes 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
230000002401 inhibitory effect Effects 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
102100023995 Beta-nerve growth factor Human genes 0.000 description 9
108090000538 Caspase-8 Proteins 0.000 description 9
102000004091 Caspase-8 Human genes 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 9
-1 MORT-1 Proteins 0.000 description 9
108010025020 Nerve Growth Factor Proteins 0.000 description 9
102000001253 Protein Kinase Human genes 0.000 description 9
230000003013 cytotoxicity Effects 0.000 description 9
231100000135 cytotoxicity Toxicity 0.000 description 9
201000010099 disease Diseases 0.000 description 9
239000003814 drug Substances 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
238000011065 in-situ storage Methods 0.000 description 9
230000001939 inductive effect Effects 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
239000000203 mixture Substances 0.000 description 9
230000011664 signaling Effects 0.000 description 9
101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 8
102100039556 Galectin-4 Human genes 0.000 description 8
101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 8
101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 8
102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
229940079593 drug Drugs 0.000 description 8
238000011534 incubation Methods 0.000 description 8
230000007246 mechanism Effects 0.000 description 8
230000026731 phosphorylation Effects 0.000 description 8
238000006366 phosphorylation reaction Methods 0.000 description 8
108060006633 protein kinase Proteins 0.000 description 8
238000002741 site-directed mutagenesis Methods 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000000758 substrate Substances 0.000 description 8
102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 7
108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 7
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 7
102000035181 adaptor proteins Human genes 0.000 description 7
108091005764 adaptor proteins Proteins 0.000 description 7
210000004899 c-terminal region Anatomy 0.000 description 7
238000010367 cloning Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000037361 pathway Effects 0.000 description 7
208000030507 AIDS Diseases 0.000 description 6
102100030762 Apolipoprotein L1 Human genes 0.000 description 6
101100237637 Bos taurus APOL gene Proteins 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
235000020958 biotin Nutrition 0.000 description 6
239000011616 biotin Substances 0.000 description 6
229960002685 biotin Drugs 0.000 description 6
230000008859 change Effects 0.000 description 6
238000010586 diagram Methods 0.000 description 6
239000000411 inducer Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
230000004952 protein activity Effects 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
101150013553 CD40 gene Proteins 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
102000008300 Mutant Proteins Human genes 0.000 description 5
108010021466 Mutant Proteins Proteins 0.000 description 5
102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
239000004365 Protease Substances 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
239000012472 biological sample Substances 0.000 description 5
101150055276 ced-3 gene Proteins 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
210000000805 cytoplasm Anatomy 0.000 description 5
238000013461 design Methods 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
230000009931 harmful effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000031146 intracellular signal transduction Effects 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
102100026189 Beta-galactosidase Human genes 0.000 description 4
101150094690 GAL1 gene Proteins 0.000 description 4
102100028501 Galanin peptides Human genes 0.000 description 4
101100121078 Homo sapiens GAL gene Proteins 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
108060001084 Luciferase Proteins 0.000 description 4
239000005089 Luciferase Substances 0.000 description 4
102000018697 Membrane Proteins Human genes 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 4
108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 4
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000006721 cell death pathway Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
230000034994 death Effects 0.000 description 4
239000000539 dimer Substances 0.000 description 4
108010052621 fas Receptor Proteins 0.000 description 4
102000018823 fas Receptor Human genes 0.000 description 4
239000007850 fluorescent dye Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 4
238000010166 immunofluorescence Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000006662 intracellular pathway Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000035699 permeability Effects 0.000 description 4
108020003519 protein disulfide isomerase Proteins 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
230000032258 transport Effects 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 3
230000004568 DNA-binding Effects 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
101150009006 HIS3 gene Proteins 0.000 description 3
108700010909 HTLV-1 proteins Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 3
101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
108091054455 MAP kinase family Proteins 0.000 description 3
102000043136 MAP kinase family Human genes 0.000 description 3
108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 3
239000012190 activator Substances 0.000 description 3
231100000354 acute hepatitis Toxicity 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
230000003321 amplification Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003833 cell viability Effects 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
101150066555 lacZ gene Proteins 0.000 description 3
229920006008 lipopolysaccharide Polymers 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
229960004452 methionine Drugs 0.000 description 3
238000000386 microscopy Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
150000002894 organic compounds Chemical class 0.000 description 3
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
238000012552 review Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000004654 survival pathway Effects 0.000 description 3
108091006106 transcriptional activators Proteins 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical group ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
102000010170 Death domains Human genes 0.000 description 2
108050001718 Death domains Proteins 0.000 description 2
108010008488 Glycylglycine Proteins 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
101000590272 Homo sapiens 26S proteasome non-ATPase regulatory subunit 2 Proteins 0.000 description 2
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
230000005049 JUN phosphorylation Effects 0.000 description 2
108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 2
108090000362 Lymphotoxin-beta Proteins 0.000 description 2
102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
102000010049 MAP kinase kinase kinase kinase activity proteins Human genes 0.000 description 2
108040005742 MAP kinase kinase kinase kinase activity proteins Proteins 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 2
102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
108090000315 Protein Kinase C Proteins 0.000 description 2
102000003923 Protein Kinase C Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102100035100 Transcription factor p65 Human genes 0.000 description 2
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 2
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
108010053098 biotin receptor Proteins 0.000 description 2
244000309466 calf Species 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
108091006116 chimeric peptides Proteins 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000000975 dye Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
108020005243 folate receptor Proteins 0.000 description 2
102000006815 folate receptor Human genes 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
229940043257 glycylglycine Drugs 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
102000058099 human PSMD2 Human genes 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000007124 immune defense Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000013198 immunometric assay Methods 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
238000003670 luciferase enzyme activity assay Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
230000002020 noncytotoxic effect Effects 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
238000002515 oligonucleotide synthesis Methods 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
235000019419 proteases Nutrition 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010998 test method Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
102000008102 Ankyrins Human genes 0.000 description 1
108010049777 Ankyrins Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
101100221077 Arabidopsis thaliana CML12 gene Proteins 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101150046268 BCK1 gene Proteins 0.000 description 1
108090000426 Caspase-1 Proteins 0.000 description 1
102100029855 Caspase-3 Human genes 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
101710104316 Cell surface-binding protein Proteins 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
101150103317 GAL80 gene Proteins 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 1
101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
230000004950 I-kappaB phosphorylation Effects 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
102000003959 Lymphotoxin-beta Human genes 0.000 description 1
102100026894 Lymphotoxin-beta Human genes 0.000 description 1
102000018721 Macroglobulins Human genes 0.000 description 1
108010091934 Macroglobulins Proteins 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
101710154541 Modulator protein Proteins 0.000 description 1
YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
101100345683 Mus musculus Mapk1 gene Proteins 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
101100348866 Nicotiana tabacum NPK1 gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108010002519 Prolactin Receptors Proteins 0.000 description 1
102100029000 Prolactin receptor Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
101150090127 STE11 gene Proteins 0.000 description 1
101100453925 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KIN3 gene Proteins 0.000 description 1
101100219192 Schizosaccharomyces pombe (strain 972 / ATCC 24843) byr2 gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 1
108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
102000011409 Transcobalamins Human genes 0.000 description 1
108010023603 Transcobalamins Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000007801 affinity label Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
238000002959 beta galactosidase induction Methods 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000010822 cell death assay Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
230000005889 cellular cytotoxicity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
238000000749 co-immunoprecipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
239000000039 congener Substances 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011981 development test Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000000447 dimerizing effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000001159 endocytotic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
229940014144 folate Drugs 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000006525 intracellular process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000001466 metabolic labeling Methods 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
235000007708 morin Nutrition 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940054441 o-phthalaldehyde Drugs 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
150000003141 primary amines Chemical group 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000003571 reporter gene assay Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000007655 standard test method Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000032895 transmembrane transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP53509997A 1996-04-02 1997-04-01 Ｔｎｆ受容体関連因子（ｔｒａｆ）のモジュレーター、その製造法および使用 Expired - Lifetime JP4180114B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
IL11780096A IL117800A0 (en)	1996-04-02	1996-04-02	Modulators of TNF receptor associated factor (TRAF) their preparation and use
IL117800		1996-04-02
IL11913396A IL119133A0 (en)	1996-08-26	1996-08-26	Modulators of TNF receptor associated factor (TRAF) their preparation and use
IL119133		1996-08-26
PCT/IL1997/000117 WO1997037016A1 (en)	1996-04-02	1997-04-01	Modulators of tnf receptor associated factor (traf), their preparation and use

Publications (2)

Publication Number	Publication Date
JP2000507826A JP2000507826A (ja)	2000-06-27
JP4180114B2 true JP4180114B2 (ja)	2008-11-12

Family

ID=26323248

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP53509997A Expired - Lifetime JP4180114B2 (ja)	1996-04-02	1997-04-01	Ｔｎｆ受容体関連因子（ｔｒａｆ）のモジュレーター、その製造法および使用

Country Status (22)

Country	Link
US (2)	US7485456B1 (et)
EP (1)	EP0894130B1 (et)
JP (1)	JP4180114B2 (et)
CN (1)	CN1197966C (et)
AT (1)	ATE380866T1 (et)
AU (1)	AU732793B2 (et)
BG (1)	BG64755B1 (et)
BR (1)	BR9708518A (et)
CA (1)	CA2250085C (et)
CZ (3)	CZ299094B6 (et)
DE (1)	DE69738370T2 (et)
DK (1)	DK0894130T3 (et)
EA (1)	EA004309B1 (et)
EE (1)	EE04783B1 (et)
ES (1)	ES2294796T3 (et)
HU (1)	HU226328B1 (et)
NO (1)	NO327054B1 (et)
NZ (1)	NZ331902A (et)
PT (1)	PT894130E (et)
SK (3)	SK287889B6 (et)
UA (1)	UA71889C2 (et)
WO (1)	WO1997037016A1 (et)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA71889C2 (uk) *	1996-04-02	2005-01-17	Йєда Рісерч Енд Дівелопмент Ко. Лтд.	Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
US5843721A (en) *	1997-07-03	1998-12-01	Tularik Inc.	Nucleic acids encoding human NIK protein
JP2003525567A (ja) *	1997-11-07	2003-09-02	ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー	分泌蛋白およびそれらをコードするポリヌクレオチド
US6265538B1 (en) *	1998-02-27	2001-07-24	The Regents Of The University Of California	Inhibitor of the inflammatory response induced by the TNFA and IL-1
DE69928244T2 (de) *	1998-05-06	2006-08-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Inhibitoren der nf-kb aktivierung
AU767973B2 (en) *	1998-08-18	2003-11-27	Abbott Gmbh & Co. Kg	TPL-2/COT kinase and methods of use
IL131719A0 (en)	1999-09-02	2001-03-19	Yeda Res & Dev	Iren protein its preparation and use
GB9930616D0 (en) *	1999-12-24	2000-02-16	Mathilda & Terence Kennedy Ins	Activation and inhibition of the immune system
US20040109854A1 (en) *	2001-02-21	2004-06-10	Zang-Hee Lee	Novel traf6 inhibiting protein
CA2447249A1 (en)	2001-06-22	2003-01-03	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Abin-mediated hepatitis protection
EP1499729B9 (en) *	2002-04-18	2012-03-14	Yeda Research And Development Co., Ltd.	Derivatives of the nf-kappab inducing enzyme, their preparation and use
PT1678209E (pt) *	2003-10-07	2011-06-30	Yeda Res & Dev	Anticorpos para a nik, a sua preparação e a sua utilização
IL158287A0 (en)	2003-10-07	2004-05-12	Yeda Res & Dev	Antibodies to nik, their preparation and use
WO2005051423A2 (en) *	2003-11-30	2005-06-09	Yeda Research And Development Co. Ltd	Methods and agents for immune modulation and methods for identifying immune modulators
IL173104A0 (en) *	2006-01-12	2006-06-11	Yeda Res & Dev	Siva and ubiquintination
EP3629022A1 (en)	2008-07-25	2020-04-01	Richard W. Wagner	Protein screening methods
GB201012420D0 (en)	2010-07-23	2010-09-08	Univ Erasmus Medical Ct	Foetal heamoglobin inhibitor
AU2011293294B2 (en)	2010-08-25	2016-03-24	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
CN105200073B (zh) *	2010-09-01	2019-03-01	山东新时代药业有限公司	人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
CA2827161A1 (en)	2011-03-16	2012-09-20	F. Hoffmann-La Roche Ag	6,5-heterocyclic propargylic alcohol compounds and uses therefor
JP6157461B2 (ja)	2011-06-30	2017-07-05	ジェンザイム・コーポレーション	Ｔ細胞活性化の阻害剤
ES2657743T3 (es)	2011-07-19	2018-03-06	Philogen S.P.A.	Terapia secuencial con anti-CTLA-4 e IL-2 dirigida
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
WO2015109391A1 (en)	2014-01-24	2015-07-30	Children's Hospital Of Eastern Ontario Research Institute Inc.	Smc combination therapy for the treatment of cancer
CN105986001B (zh) *	2015-02-12	2019-12-03	上海交通大学	一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法
CN108026172B (zh)	2015-06-26	2022-04-29	赛诺菲生物技术公司	单克隆抗il-1racp抗体
MA55529A (fr)	2019-04-03	2022-02-09	Genzyme Corp	Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
CN120225564A (zh)	2022-09-21	2025-06-27	赛诺菲生物技术公司	人源化抗il-1r3抗体及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5641876A (en) *	1990-01-05	1997-06-24	Cornell Research Foundation, Inc.	Rice actin gene and promoter
WO1997004793A1 (en) *	1995-08-02	1997-02-13	Ingram Teresa J	Composition for administration to patients with chronic fatigue syndrome and acquired immune deficiency syndrome
AU6692996A (en) *	1995-08-08	1997-03-05	Tularik Inc.	Inhibitors of apoptosis
US5804412A (en) *	1996-04-01	1998-09-08	The Regents Of The University Of California	Nucleic acids encoding sorting nexins and methods of using same
UA71889C2 (uk) *	1996-04-02	2005-01-17	Йєда Рісерч Енд Дівелопмент Ко. Лтд.	Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
BR9708918A (pt)	1996-05-08	1999-08-03	Henkel Corp	Tensoativo processo para fabricar o mesmo produto e composição de limpeza
US5843721A (en) *	1997-07-03	1998-12-01	Tularik Inc.	Nucleic acids encoding human NIK protein

1997
- 1997-01-04 UA UA98105743A patent/UA71889C2/uk unknown
- 1997-04-01 EE EE9800322A patent/EE04783B1/et unknown
- 1997-04-01 NZ NZ331902A patent/NZ331902A/en not_active IP Right Cessation
- 1997-04-01 AT AT97914534T patent/ATE380866T1/de active
- 1997-04-01 CN CNB971951934A patent/CN1197966C/zh not_active Expired - Lifetime
- 1997-04-01 AU AU21755/97A patent/AU732793B2/en not_active Expired
- 1997-04-01 DK DK97914534T patent/DK0894130T3/da active
- 1997-04-01 DE DE69738370T patent/DE69738370T2/de not_active Expired - Lifetime
- 1997-04-01 CA CA002250085A patent/CA2250085C/en not_active Expired - Lifetime
- 1997-04-01 SK SK50016-2007A patent/SK287889B6/sk not_active IP Right Cessation
- 1997-04-01 EP EP97914534A patent/EP0894130B1/en not_active Expired - Lifetime
- 1997-04-01 BR BR9708518A patent/BR9708518A/pt not_active Application Discontinuation
- 1997-04-01 EA EA199800885A patent/EA004309B1/ru not_active IP Right Cessation
- 1997-04-01 JP JP53509997A patent/JP4180114B2/ja not_active Expired - Lifetime
- 1997-04-01 SK SK50017-2007A patent/SK287890B6/sk not_active IP Right Cessation
- 1997-04-01 CZ CZ20060018A patent/CZ299094B6/cs not_active IP Right Cessation
- 1997-04-01 CZ CZ20060017A patent/CZ298866B6/cs not_active IP Right Cessation
- 1997-04-01 HU HU9902429A patent/HU226328B1/hu unknown
- 1997-04-01 CZ CZ0318398A patent/CZ299682B6/cs not_active IP Right Cessation
- 1997-04-01 PT PT97914534T patent/PT894130E/pt unknown
- 1997-04-01 SK SK1361-98A patent/SK287085B6/sk not_active IP Right Cessation
- 1997-04-01 ES ES97914534T patent/ES2294796T3/es not_active Expired - Lifetime
- 1997-04-01 US US09/155,676 patent/US7485456B1/en not_active Expired - Fee Related
- 1997-04-01 WO PCT/IL1997/000117 patent/WO1997037016A1/en active IP Right Grant
1998
- 1998-09-29 NO NO19984551A patent/NO327054B1/no not_active IP Right Cessation
- 1998-10-07 BG BG102817A patent/BG64755B1/bg unknown
2009
- 2009-02-03 US US12/365,136 patent/US8236507B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
UA71889C2 (uk)	2005-01-17
PT894130E (pt)	2008-01-14
SK287890B6 (sk)	2012-03-02
EP0894130A1 (en)	1999-02-03
NO984551D0 (no)	1998-09-29
SK287889B6 (sk)	2012-03-02
JP2000507826A (ja)	2000-06-27
CN1197966C (zh)	2005-04-20
CZ318398A3 (cs)	1999-05-12
DE69738370D1 (de)	2008-01-24
SK287085B6 (sk)	2009-11-05
US20090291888A1 (en)	2009-11-26
WO1997037016A1 (en)	1997-10-09
US7485456B1 (en)	2009-02-03
NO327054B1 (no)	2009-04-14
ATE380866T1 (de)	2007-12-15
EA004309B1 (ru)	2004-02-26
AU732793B2 (en)	2001-05-03
CZ299094B6 (cs)	2008-04-23
HU226328B1 (en)	2008-09-29
CA2250085C (en)	2009-10-20
BR9708518A (pt)	1999-08-03
DE69738370T2 (de)	2008-12-04
DK0894130T3 (da)	2008-01-07
HUP9902429A2 (hu)	1999-10-28
SK136198A3 (en)	1999-05-07
NO984551L (no)	1998-11-24
BG64755B1 (bg)	2006-02-28
HUP9902429A3 (en)	2001-11-28
BG102817A (en)	1999-05-31
US8236507B2 (en)	2012-08-07
CZ299682B6 (cs)	2008-10-15
AU2175597A (en)	1997-10-22
CZ298866B6 (cs)	2008-02-27
ES2294796T3 (es)	2008-04-01
EE04783B1 (et)	2007-02-15
HK1018910A1 (en)	2000-01-07
EE9800322A (et)	1999-04-15
CN1221449A (zh)	1999-06-30
NZ331902A (en)	2000-02-28
EA199800885A1 (ru)	1999-04-29
CA2250085A1 (en)	1997-10-09
EP0894130B1 (en)	2007-12-12

Legal Events

Date	Code	Title	Description
2004-04-08	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040317
2007-10-23	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071023
2008-02-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080123
2008-04-01	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401
2008-07-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080627
2008-08-08	TRDD	Decision of grant or rejection written
2008-08-19	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080819
2008-08-21	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2008-09-04	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080827
2008-09-05	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2008-09-08	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110905 Year of fee payment: 3
2008-10-03	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110905 Year of fee payment: 3
2008-10-03	R154	Certificate of patent or utility model (reissue)	Free format text: JAPANESE INTERMEDIATE CODE: R154
2011-09-06	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120905 Year of fee payment: 4
2012-09-04	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130905 Year of fee payment: 5
2013-09-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-09-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-09-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-09-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-04-01	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JP4180114B2 (ja)	2008-11-12	Ｔｎｆ受容体関連因子（ｔｒａｆ）のモジュレーター、その製造法および使用
JP3980641B2 (ja)	2007-09-26	Ｆａｓ受容体およびほかのタンパク質の機能のモジュレーター
JP3787355B2 (ja)	2006-06-21	Ｆａｓ／ａｐｏ１受容体機能のモジュレーター
US20090075889A1 (en)	2009-03-19	Iren protein, its preparation and use
US20020123117A1 (en)	2002-09-05	Modulators of regulatory proteins
JP4351389B2 (ja)	2009-10-28	Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質
KR100552547B1 (ko)	2006-05-12	Tnf수용체연합된인자(traf)조절물질,이의제조및이의용도
AU767967B2 (en)	2003-11-27	Modulators of TNF receptor associated factor (TRAF), their preparation and use
US7745579B1 (en)	2010-06-29	Inhibitor of NF-KB activation
JP2009148285A (ja)	2009-07-09	Ｔｎｆ／ｎｇｆレセプターファミリーおよびほかのタンパク質のレセプター機能調節物質
IL126428A (en)	2010-02-17	Modulators of tnf receptor associated factor (traf), their preparation and use
HK1051876B (en)	2009-08-28	Iren protein, its preparation and use